Our NAV-005 antagonist binds the immunosuppressive HIO-1 factor and blocks its ability to suppress mAb, TCE and ADC ...

This new article publication from Acta Pharmaceutica Sinica B, discusses how an innovative and stable mRNA-LNP microneedle vaccine elicits humoral and multifunctional cellular immune responses.

Century Therapeutics (IPSC) aims at a durable “once-and-done” Type 1 diabetes cure with hypoimmune iPSC beta cells; runway to ...

This new article publication from Acta Pharmaceutica Sinica B, discusses the construction of a localized immune niche via supramolecular hydrogel vaccine to elicit durable and enhanced immunity ...

A simple and widely deployable microneedle (MN) vaccine delivery system (mLNP-man-MN) was developed for mannose-modified LNPs (mLNP-man) loaded with mRNA encoding the SARS-CoV-2 spike receptor-binding ...

Effect of KROS 101, a small molecule GITR ligand agonist, on T effector cells, T reg cells and intratumoral CD8 T cell cytotoxicity. Phase 1 study of DK210 (EGFR), a tumor-targeted IL2 x IL10 dual ...

mRNA vaccines developed against the spike glycoprotein of severe acute respiratory syndrome type 2 coronavirus (SARS-CoV-2), displayed remarkable efficiency in combating coronavirus 19 (COVID-19).

The in situ formed hydrogel vaccine creates an immune niche to coordinate the spatiotemporal dynamics of vaccine components and dendritic cells, eliciting durable and enhanced immunity against ...